Clinical Trials Browser

Neoplasm, Residual × pevonedistat × Clear all

NCT04712942 2023-08-21

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Phase 2 Completed

Myelodysplastic Syndromes, Neoplasm, Residual